
|Articles|February 6, 2006
FDA gives green light to anti-hepatitis B product
Advertisement
Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
FAQ: The Medicare GLP-1 Bridge—What Independent Pharmacists Need to Know
2
Grocery Pharmacy Conglomerate to Pay $40 Million for Violating False Claims Act
3
Pharmacy Law Lowdown: GLP-1 Compounding
4
HHS Claims ACIP Cannot Meet for Flu Season Due to Ongoing Legal Battle
5



































